Bortezomib (PS-341)

目录号:S1013 别名: LDP-341, MLM341

Bortezomib (PS-341) Chemical Structure

Molecular Weight(MW): 384.24

Bortezomib (PS-341)是有效的蛋白酶抑制剂,Ki为0.6 nM。它对肿瘤细胞表现出良好的选择性。

规格 价格 库存 购买数量  
RMB 571.94 现货
RMB 2188.92 现货
RMB 5488.32 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户购买Selleck的此次产品后发表的文献148篇:

客户使用该产品的25个实验数据:

  • Immunoblot analysis of cell lysates from the indicated cell lines treated with GNE-6776 (2 μ M for 18 h), either alone or in combination with a UAE1 inhibitor MLN-7243 (5 μ M for 45 min) or the proteasome inhibitor bortezomib (5 μ M for 45 min) as indicated.

    Nature, 2017, 550(7677):534-538. Bortezomib (PS-341) purchased from Selleck.

    Indisulam dependent degradation of RBM39 can be blocked by bortezomib, a proteasome inhibitor. Cells were pretreated with indicated concentrations of bortezomib for 2 hours, followed by 6 hours of treatment with 2 μM indisulam. The effect of bortezomib is attenuated in a bortezomib resistant cell line.

    Science, 2017, eaal3755. Bortezomib (PS-341) purchased from Selleck.

  • Wild-type mice fed as indicated were injected with vehicle (10% DMSO, pH 7.4 PBS) or bortezomib (5 mg/kg bodyweight). Livers were collected 16 hr later for quantitative PCR analysis of indicated genes (n = 4–5). *p < 0.05 bortezomib effect and #p < 0.05 Chol-Diet effect by two-way ANOVA.

    Cell, 2017, 171(5):1094-1109. Bortezomib (PS-341) purchased from Selleck.

    Effect of different proteasome inhibitors on dysferlin expression and on membrane resealing in cultured primary myoblasts. Primary myoblasts from patient 2 harboring a homozygous Arg555Trp DYSF mutation that were treated with the indicated amounts of bortezomib for 24 hours. Western blots of protein extracts were stained with anti-dysferlin antibodies and with anti–a-tubulin antibody as loading control.

    Sci Transl Med 2015 6(250), 250ra112. Bortezomib (PS-341) purchased from Selleck.

  • Pharmacologic inhibition of the proteasome blocks proplatelet formation in murine and human megakaryocytes. Human megakaryocytes were pretreated with vehicle or bortezomib, and megakaryocytes producing proplatelets (PP) were examined. Shown are representative transmission images and representative confocal images with wheat germ agglutinin (WGA; red) and phalloidin (green) staining. Scale bars: 50 um.

    J Clin Invest 2014 124(9), 3757-66. Bortezomib (PS-341) purchased from Selleck.

    Immunofluorescence showing HDAC4 localization in mouse primary osteoblasts treated with vehicle or PTH alone or in the presence of bortezomib. Primary osteoblasts treated with vehicle, PTH, or PTH plus bortezomib for 2 h using anti-HDAC4 and anti-b-actin antibodies.

    J Cell Biol 2014 205(6), 771-80. Bortezomib (PS-341) purchased from Selleck.

  • Effects of NF-kB inhibition on cell proliferation and apoptosis in Foxp3cKO prostate. A. Top left panels: Representative H&E staining of PIN lesions in ventral prostates of 60-week-old PBS- or bortezomib-treated Foxp3cKO littermates. Scale bar, 50 祄. Right graph: Quantification of Ki67-positive cells identified by IHC analysis (bottom left panels) as a measure of cell proliferation, performed with Scion Image software. Horizontal lines represent the average values. The p value was determined by two-tailed t test. B. Representative western blots showing p65 and nuclear p65 (N-p65) expression in prostates at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. C. Quantification of Bcl2l1 and Traf1/2 mRNA expression as a percentage of Hprt expression measured in microdissected mouse prostate epithelial cells by qPCR at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. Horizontal lines represent the average values. The p values were determined by two-tailed t test. D. Left panels: Representative images of TUNEL assays performed on prostates from PBS- or bortezomib-treated mice at 60 weeks of age. Insets show the apoptotic cells (green) in prostate glands. Scale bar, 100 祄. Right graph: Quantification of apoptotic cells in the ventral and dorsolateral prostates of PBS- or bortezomib-treated mice at 45 and 60 weeks of age. Horizontal lines represent the average values. The p value was determined by two-tailed t test. cKO, PB4-Cre4+Foxp3flox/y; wks, weeks; B/P, ratio of the mean value from bortezomib-treated mice to the mean value in PBS-treated mice. All experiments were repeated two times. Wks, weeks.

    Cancer Res 2015 75(8), 1714-24. Bortezomib (PS-341) purchased from Selleck.

    Inhibition of proteasome and lysosome or silencing of VCP and co-factors lead to the accumulation of OP-puro-labeled DRIPs adjacent to or within SGs. HeLa cells were co-treated for 45 min with OP-puro and arsenite (Ars.); where indicated, cells were pretreated with bortezomib (Bort.) overnight and/or ammonium chloride (NH4Cl) for 2 h 15 min. Cells were fixed and labeled with Alexa594-Azide and anti-TIA-1.

    Cell Death Differ 2014 21(12), 1838-51. Bortezomib (PS-341) purchased from Selleck.

  • Control wild-type and Fmn2–/–oocytes observed at different stages of meiotic maturation [prophase I (Pro I), NEBD, 3 hours and 8 hours after NEBD] using anti-Fmn2. wt + Bortezo, wild-type oocytes treated with 0.1μM Bortezomib for 90 minutes before fixation. All oocytes were observed using the same settings and the images treated the same way (three independent experiments). Red arrows indicate cortical labeling. Scale bar: 10μm.

    Development 2011 138, 2903-2908. Bortezomib (PS-341) purchased from Selleck.

    Immunofluorescence analysis for Ser536 p-NF-κB cellular localization of RS4;11cells treated with CX-4945 (5 μM) and bortezomib (2.5 nM) either alone or in combination. Cells were treated, collected at 22 h and reacted with an antibody to Ser536 p-NF-κB which was revealed by a Cy3-conjugated secondary antibody. DAPI was used to label nuclei.

    Oncotarget, 2015, 51: S659-S660. Bortezomib (PS-341) purchased from Selleck.

  • (B–C) LNCaP (B) and LNCaP-AI (C) cells were transiently transfected with sPLA2-IIa(-800)-Luc (0.5 μg). The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) without or with EGF (100 ng/ml) for 24 h. Luciferase assay was performed according to a standard protocol with Renilla luciferase as an internal control. Data are presented as the mean (±SD) of duplicate values of a representative experiment that was independently repeated for five times.

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

    LNCaP-AI cells were starved in 1% stripped medium for 24 h. The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) for 24 h. Cell culture medium was collected from each sample and subjected to ELISA for sPLA2-IIa. The condition medium samples were diluted 10 times for ELISA. Average of duplicate samples was converted to nanogram per milliliter against standard curve. The data represent one of five repeated experiments.

     

     

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

  • Cell viability of HCT116 cells treated with a single drug or with the addition of leucovorin.

    Sci Rep, 2017, 7(1):682. Bortezomib (PS-341) purchased from Selleck.

    The stable cell line HepAD38 was incubated for 18 h in the presence of the indicated amount of Bortezomib. The medium was removed and replaced by medium containing Bortezomib dissolved in PBS. In case of the control cells the same amount of PBS was added to the medium. 4 h later this procedure was repeated and again 14 h later the supernatant was collected. The amount of viral particles was quantified by real time PCR. HBV-genome quantification was done using COBAS® AmpliPrep/COBAS® TaqMan® HBV test (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer’s instructions. The assay shows relative values (the value for untreated control cells was arbitrarily set as 1) that are based on three independent experiments. The cell viability was analyzed by MTT assays. For does up to 50 nM no significant effect on cell viability was observed within 18h, for 100 nM the proportion of metabolically active cells was reduced to 83%.

    J Biol Chem 2010 285, 41074-41086. Bortezomib (PS-341) purchased from Selleck.

  • PS-341 impairs FPV replication in A549 cells. (A and B)A549 cells were either pretreated for 1 h with different concentrations of PS-341 or with solvent only or were left untreated. Then, cells were infected with FPV at an MOI of 0.001 (A) or 0.05 (B). After virus inoculation cells were posttreated with different concentrations of PS-341. (A) At 24 h p.i. supernatants were obtained and progeny virus titers were measured by standard plaque assay. (B)Proteasome activity and the ability of PS-341 to inhibit the proteasome was determined 24 h p.i. (C) A549 cells were pretreated with 50 nM PS-341 or solvent or left untreated for 1 h. Afterwards cells were infected with FPV at an MOI of 0.0005. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or solvent or left untreated. After the indicated times p.i.supernatants were obtained and progeny virus titers were determined by standard plaque assay. Arrow bars in all experiments represent standard deviations of three independent experiments.

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

    Early steps of viral replication within the first replication cycle are affected. (A) For time-of-addition kinetics analysis, A549 cells were either left untreated or were pretreated for 10 h or 1 h with 50 nM PS-341 before infection and additionally posttreated after infection. Cells were infected with FPV at an MOI of 0.005. After virus inoculation cells were posttreated with 50 nM PS-341. Then the proteasome inhibitor was added after virus inoculation (10 h, 1 h, and 30 min) or it was added at the different times p.i. as indicated (1 h, 2 h, 4 h, 6 h, and 8 h; cells were not pretreated before infection). At 9 h p.i. supernatants were obtained and progeny virus titers were determined by standard plaque assay. Shown is one representative experiment out of three independent experiments. (B) A549 cells were pretreated with 50 nM PS-341 or left untreated for 1 h. Afterwards cells were infected with avian FPV or human PR8 at an MOI of 1. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or left untreated. After the indicated times p.i. cells were lysed and analyzed by Western blotting for accumulation of viral proteins polymerase PB1 and matrix protein M1. Cellular protein ERK2 served as a control to demonstrate equal amounts of protein loading. Shown is one representative blot out of three independent experiments.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

  • A549 cells were treated with PS-341 at 50 nM for the indicated times or left untreated. Western blotting was performed with total cell lysates, using phospho-specific antibodies against JNK and the transcription factors c-Jun and ATF-2 or loading controls, respectively.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

    Western blot of extracts of infected cells treated with different proteasome inhibitors at different concentrations, reacted with the indicated antibodies. p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • Time window treatment with proteasome inhibitors. (A) Scheme of the experiment performed with MA104 cells exposed to virus (OSU; MOI, 3) for 1 h and analyzed at the starting point and endpoint of the indicated time window treatments with DMSO, MG132, or bortezomib. (B) Western blot of cellular lysates derived from cells infected for the indicated time periods and treated with the proteasome inhibitors or DMSO. NI, noninfected cells. Blots were reacted with the indicated antibodies; p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    Fluorescence analysis of viroplasm formation on NSP5-EGFP cells infected with rotavirus (OSU; MOI, 3) and treated or not treated with MG132 (10 M) or bortezomib (10 M) at different times p.i., as indicated. Cells were analyzed at the starting points (1 h, 3 h, 5 h, 7 h) and endpoints (9 h) of the inhibitor’s window treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • Quantification of the accumulation of viroplasms in infected NSP5 -EGFP/MA104 cells. At different times p.i., cells were treated for 4 h with DMSO or the indicated proteasome inhibitor and the number of viroplasms/cell was quantified at the starting (1 h, 3 h, 5 h; white bars) and endpoints (5 h, 7 h, 9 h) of treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    Proteasome inhibition effect on biotinylation of MHC-Iα. (a) WB-ra of cellular extracts of HEK293 cells co-transfected with BAP-MHC-Ia and cyt-BirA (control) and, where indicated, with US2 or US11 in the absence (2) or presence of MG132 (MG; 50 μM for 4 h) or Bortezomib(Bort.; 50 μM for 4 h).

    PLoS One 2011 6, e23712. Bortezomib (PS-341) purchased from Selleck.

  • HLC-1 cells were treated with IFN-gamma (30 ng/ml) and Bortezomib (0-10 nM) for 3 h. After washing with PBS, the cells were cultured for another 45 h in the fresh medium. After 48 h incubation, PD-L1 expression was analysed by flow cytometry (n =3).

    Int Immunopharmacol, 2018, 54:39-45. Bortezomib (PS-341) purchased from Selleck.

     

    KKU-M213 was treated with BTZ as indicated. Total cell lysate ( a) and nuclear extract (b) were prepared. Actin and γ -tubulin were loading controls for total and nuclear proteins, respectively.

    2011 Mireia Vila Gasull University of Porto. Bortezomib (PS-341) purchased from Selleck.

  • Mireia Vila Gasull University of Porto. 2011;Mireia Vila Gasull . Bortezomib (PS-341) purchased from Selleck.

产品安全说明书

Proteasome抑制剂选择性比较

生物活性

产品描述 Bortezomib (PS-341)是有效的蛋白酶抑制剂,Ki为0.6 nM。它对肿瘤细胞表现出良好的选择性。
靶点
20S proteasome [1]
(Cell-free assay)
0.6 nM(Ki)
体外研究

Bortezomib,一种硼酸二肽,是一种26S蛋白酶体的高选择性可逆抑制剂,其作用于错误折叠蛋白的降解,并且对细胞周期的调控是必要的。暴露于Bortezomib能够稳定p21,p27,和p53,以及促凋亡Bid和Bax蛋白,微囊蛋白-1,和抑制剂κB-α,这防止了核因子κB诱导的细胞存活途径的激活。Bortezomib也会促进促凋亡c-Jun-NH2末端激酶,以及内质网应激反应的激活。这些细胞蛋白水平的改变导致对增殖,迁移的抑制,和癌细胞凋亡的促进。[2] Bortezomib能够渗透到细胞,并抑制蛋白酶体介导的细胞内长寿蛋白水解,抑制50%蛋白质水解的浓度为∼0.1 μM。Bortezomib对衍生自美国国家癌症研究所(NCI)多重人类肿瘤的一组60个癌细胞系的IC50值为7 nM。PC-3细胞用Bortezomib (100 nM)处理8小时导致细胞积聚在G2-M期,相应的G1期细胞数量减少。Bortezomib在24和48小时杀死PC-3细胞,IC50分别为100和20 nM。Bortezomib治疗16-24小时后诱导细胞核缩合。Bortezomib在低至100 nM浓度下以时间依赖的方式导致PARP裂解,在处理24小时后产生效果。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 NYPNTJI2S3m2b4TvfIlkKEG|c3H5 MmewOVAh|ryP NIDBZo01QCCq NFSwSmdFVVOR MXPLbYxteyClZXzsd{BjgSCvb4LlJJRp[W5iOUml MYWxNFQ6QTZ2Mx?=
OVCA 429 MkjCSpVv[3Srb36gRZN{[Xl? NV\QVVVoOzByIH7N M2\jVVQ5KGh? NYD4TJhCTE2VTx?= MmX2SIl{enWydIOgbY51[WO2IH31cJRq[2WubIXsZZIhfHWvb4Kgd5Bp\XKxaXTz M1q3dVExQTl7N{[2
RPMI8226 M4eyeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVH6eFc5OTByIH7N NGPBcFI1QCCq MYHEUXNQ NHfrN2tKSzVyPUOwJI5O NVXNZ3lVOTF|ME[0PFk>
Dox40 M3rIS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfVNVAxKG6P NGrOU2M1QCCq NWDyc4w3TE2VTx?= M17rOGlEPTB;NECgcm0> MnjlNVE{ODZ2OEm=
MR20 NGrEUYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWqxNFAhdk1? M2XjZ|Q5KGh? NEX2WFZFVVOR M3TxZWlEPTB;MkCgcm0> MXyxNVMxPjR6OR?=
LR5 MkTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLVNVAxKG6P NUfzeVBvPDhiaB?= NHjifXFFVVOR Ml3YTWM2OD1{MDDuUS=> MVSxNVMxPjR6OR?=
U266 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUn2cnhvOTByIH7N MmfvOFghcA>? NXnUSJdpTE2VTx?= NXG3OW9GUUN3ME2zJI5O NEX2ZXMyOTNyNkS4PS=>
IM-9 M3T1WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPTXWwyODBibl2= M{H3ZlQ5KGh? MVnEUXNQ MUXJR|UxRTZibl2= MV:xNVMxPjR6OR?=
Hs Sultan M{nBWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn75NVAxKG6P NVv0SFJVPDhiaB?= MnfPSG1UVw>? MWXJR|UxRTJyIH7N NHXSVnkyOTNyNkS4PS=>
PAM-LY2 NVex[2dHTnWwY4Tpc44hSXO|YYm= MU[xNFAhdk1? Ml[1NVIhcA>? MmDWSG1UVw>? NUj6bm1GUW6qaXLpeJMhVkZvzsrCJIFkfGm4YYTpc44> MojpNVE{PTB7MUO=
PAM 212 Mo\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NImxN|EyODBibl2= MXW3NkBp M2\tT2ROW09? NWflepRNUW6qaXLpeJMh[2WubDD2bYFjcWyrdIm= NHjoVosyOTN3MEmxNy=>
PAM-LY2 NF3KUodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrEPHkyODBibl2= NWrtenR2PzJiaB?= NX;4NWNjTE2VTx?= NVzsfG5vUW6qaXLpeJMh[2WubDD2bYFjcWyrdIm= NFXkfJEyOTN3MEmxNy=>
B4B8 NH3iUIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVOxNFAhdk1? MU[3NkBp NHrzXHlFVVOR MWPJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? NV7nUYV4OTF|NUC5NVM>
B7E3 MnK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7GeWY2OTByIH7N M3rJbFczKGh? MWfEUXNQ Mmm0TY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? NV24XZFxOTF|NUC5NVM>
UM-SCC-9 M2K1VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHsco0yODBibl2= NFnKc|A4OiCq NFjyeo9FVVOR M3TveWlvcGmkaYTzJINmdGxidnnhZoltcXS7 NUXuV4V2OTF|NUC5NVM>
UM-SCC-11B NG\ie3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7OSlEyODBibl2= MmD3O|IhcA>? NUP3[oFPTE2VTx?= M4jkc2lvcGmkaYTzJINmdGxidnnhZoltcXS7 NFv2R3YyOTN3MEmxNy=>
H460 MVvGeY5kfGmxbjDBd5NigQ>? MnO0NVAh|ryP M3rOfFI1KGh? MlewSG1UVw>? NFjpUFFKdmS3Y3XzJGJkdC1{IIDoc5NxcG:{eXzheIlwdiCjbnSgZ4xm[X[jZ3WgZ49zemWuYYTl[EB4cXSqIFeyMW0heGijc3WgZZJz\XO2 M2jHdlEzPDl{MUG3
U266 NX:5ZmJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\LbVI2ODBibnevcYw> Ml7VOFghcA>? Mmi1SG1UVw>? M2\UOGlvcGmkaYTzJINmdGxiZ4Lve5Rp M4[2XlEzPjNzNkG5
ARH77 Ml3DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnnT|E2ODBibnevcYw> MXO0PEBp MVLEUXNQ MWfJcohq[mm2czDj[YxtKGe{b4f0bC=> MVexNlY{OTZzOR?=
WAD-1 NEDPfGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zxZVUxOCCwZz;tcC=> MXW0PEBp MXTEUXNQ NXXRfWNyUW6qaXLpeJMh[2WubDDndo94fGh? MVSxNlY{OTZzOR?=
U266/LR7 M4DO[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2W4S|UxOCCwZz;tcC=> NEL6RXc1QCCq M4PQeGROW09? NFfBc5FKdmirYnn0d{Bk\WyuIHfyc5d1cA>? MVKxNlY{OTZzOR?=
U266/dox4 M3HYfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjXOVAxKG6pL33s NHz0dJg1QCCq MWPEUXNQ M2r5TWlvcGmkaYTzJINmdGxiZ4Lve5Rp NVK2d4JMOTJ4M{G2NVk>
RPMI8226/LR5 MnqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPMd4c2ODBibnevcYw> MVS0PEBp NULySmJzTE2VTx?= NGi2b2NKdmirYnn0d{Bk\WyuIHfyc5d1cA>? MWqxNlY{OTZzOR?=
H460 M4PRbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PqdlExKM7:TR?= M{POUFczKGh? M4TOUmROW09? NHjQW5FKSzVyPUGwNEBvVQ>? NGPZVJUyOjZ|MU[yNC=>
H358 NHH2[HNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;NNVAh|ryP M3HnfVczKGh? M{TxW2ROW09? MWPJR|UxRTdyIH7N MWqxNlY{OTZ{MB?=
H322 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7Lb5AyOTBizszN MYi3NkBp NFfs[VJFVVOR MnHwTWM2OD14MkCgcm0> NIDy[VMyOjZ|MU[yNC=>
H460 MWPGeY5kfGmxbjDBd5NigQ>? MVuxNFAhdk1? NGTaNFgzPCCq M{PIe2ROW09? NIX3T2xKdmS3Y3XzJGczNU1vcHjhd4Uh[XK{ZYP0JIFv\CC2dXL1cIlvKGG|c3XtZox6NWSrc3Hzd4Vu[my7 MUWxNlY{OTZ{MB?=
LNCap-Pro5 M{nKdGZ2dmO2aX;uJGF{e2G7 M1;lflEh|ryP MV[0JIg> NWi3NXBDTE2VTx?= MV\TeIFjcWyrenXzJJA2Ow>? NULnUJNjOTR4MUK1N|I>
T29 NXTQNZh5SXCxcITvd4l{KEG|c3H5 NUPSc3JwPTBibl2= M4ThfFQ5KGhi MmfLSG1UVw>? MYTJcoR2[2W|IHPlcIwh[XCxcITvd4l{ M3vVdlE3Pzd6MUe5
T29Kt1 NFPDWWhCeG:ydH;zbZMhSXO|YYm= MWi1NEBvVQ>? NWrZOXpxPDhiaDC= MXfEUXNQ NUfRdWhiUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MXuxOlc4QDF5OR?=
HCT116 NWLlOlkySXCxcITvd4l{KEG|c3H5 MWe1NEBvVQ>? MknOOFghcCB? NFz1elhFVVOR M{TuOWlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? M1zjOFE3Pzd6MUe5
HKe-3 NV63WlVVSXCxcITvd4l{KEG|c3H5 NV;EZ5lZPTBibl2= NY\oVnJQPDhiaDC= M4XJZmROW09? MU\JcoR2[2W|IHPlcIwh[XCxcITvd4l{ M{Tn[VE3Pzd6MUe5
NB-1691 MkP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HVV|Eh|ryP Ml7MO|IhcA>? MnXmTY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJJRwKDVn M1zwO|E4Pjh7Nki0
CHLA-255 MnXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4G1TlEh|ryP M4HsZVczKGh? MmOzTY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJJRwKDJn NE[yZ2cyPzZ6OU[4OC=>
SK-N-AS NXHUeHlYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWP2XGhJOSEQvF2= NH7tbJg4OiCq Ml:4TY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJJRwKDFyJR?= NYW1U3RTOTd4OEm2PFQ>
NB-1691 NGfuUWFHfW6ldHnvckBCe3OjeR?= Mor0NVAhdk1? MWeyOEBp NFzj[JFUcWewaX\pZ4FvfGy7IILl[JVk\XNiY3XscJMhcW5idHjlJGcxN0dzIIDoZZNm MUOxO|Y5QTZ6NB?=
CHLA-255 M2HHe2Z2dmO2aX;uJGF{e2G7 M4rNPFExKG6P NEnwbHMzPCCq NVvUe45sVW:mZYP0cJkhemWmdXPld{Bk\WyuczDpckB1cGViR{CvS|EheGijc3W= MkK4NVc3QDl4OES=
RPMI 8226 M3nxd2Z2dmO2aX;uJGF{e2G7 MoDONlAhdk1? NVvCS4VHQCCq NWPZXIZbW2mpbnnmbYNidnSueTDlcohidmOnczDOSk3PwkJiYXP0bZZqfHl? NYTJO4pGOTl2M{[wOVA>
MM.1S NGjvWWdHfW6ldHnvckBCe3OjeR?= M2fpcVIxKG6P MnHGPEBp NF64SmNUcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>? M2qxUlE6PDN4MEWw
U266 NWDhNIZFTnWwY4Tpc44hSXO|YYm= NYHmT3BrOjBibl2= NHTnS5E5KGh? M3HNbXNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6 MV2xPVQ{PjB3MB?=
OPM1 MYLGeY5kfGmxbjDBd5NigQ>? MlL6NlAhdk1? NIr3OJo5KGh? NXXTdph{W2mpbnnmbYNidnSueTDlcohidmOnczDOSk3PwkJiYXP0bZZqfHl? MkTMNVk1OzZyNUC=
INA6 NIryd4hHfW6ldHnvckBCe3OjeR?= M{\pOFIxKG6P MnrEPEBp NGnNcopUcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>? NIXxWJMyQTR|NkC1NC=>
OPM2 M3jvSGZ2dmO2aX;uJGF{e2G7 MnfvNlAhdk1? MVi4JIg> M1TLOXNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6 NVu1SJgzOTl2M{[wOVA>
RPMI 8226 MnLhSpVv[3Srb36gRZN{[Xl? M2[4TVIxKG6P M4Hnc|ghcA>? MmjwTY5lfWOnczDEUmEhe3mwdHjld4l{ NULL[ZhiOTl2M{[wOVA>
BaF/3 NEXae3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXqxNFAhdk1? MnezOFghcA>? NW\mWXBQUUN3ME22MlIhdk1? NGG3XlMzODNyNU[5Ni=>
BaF/3-p210 M1H5N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDtNVAxKG6P MYW0PEBp M4n0b2lEPTB;ND63JI5O NVfJeI9MOjB|MEW2PVI>
TCC-S NXrUOZh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY[xNFAhdk1? NXrGWFBnPDhiaB?= Mme3TWM2OD1{Lkigcm0> M{KxSlIxOzB3Nkmy
BaF/3 MV;GeY5kfGmxbjDBd5NigQ>? NU\YbXBZPiCwTR?= NXfZ[ZNHPDhiaB?= MVPJcoR2[2W|IHGg[5Jm[XRiR{GgZ4VtdC2leXPs[UBienKnc4S= M1vsOVIxOzB3Nkmy
BaF/3-p210 M2f3WmZ2dmO2aX;uJGF{e2G7 MoWyOkBvVQ>? M4rHRVQ5KGh? NETpR2tKdmS3Y3XzJIEhe2yrZ3j0JGcyKGOnbHytZ5lkdGViYYLy[ZN1 NF6xPIczODNyNU[5Ni=>
BaF/3-p210 M134WGZ2dmO2aX;uJGF{e2G7 NUntcVdTPiCwTR?= M4KxfFI1KGh? MnfwVoVlfWOnczD0bIUheGixc4Doc5J6dGG2aX;uJIFv\CC2aHWgZYN1cX[rdImgc4YhWmJ? MmnZNlA{ODV4OUK=
Raji NWnpbY5oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzNNUDPxE1? MnTCNlQhcA>? M3LaOHJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= NXvsWmkxOjFzN{C5PFg>
LCL-1 NITNTZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUGxJO69VQ>? NFzjbowzPCCq NIm0c|VT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= NYe0PYltOjFzN{C5PFg>
LCL-2 NYHQRXFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjldpgyKM7:TR?= MkSwNlQhcA>? MUTS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? M{H4WVIyOTdyOUi4
BJAB M3vxdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TwTFEh|ryP NHLMWG8zPCCq MXjS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? M1XiRVIyOTdyOUi4
SNT-13 MkjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\lNUDPxE1? MmXpNlQhcA>? Mn3rVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi M{nPdVIyOTdyOUi4
SNT-16 NH\VVItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYC0N3ltOSEQvF2= MX[yOEBp NEHhd3hT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= MXqyNVE4ODl6OB?=
Jurkat NVzYVo85T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7ONUDPxE1? NXLYdnJPOjRiaB?= M1fGUXJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= NFrCRm4zOTF5MEm4PC=>
KAI-3 NYm1XJh{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2n0XlEh|ryP NFG0S2wzPCCq NWTzc3pYWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg MnLrNlEyPzB7OEi=
SNK-6 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzmXWp4OSEQvF2= NF\EXYMzPCCq NGO5U|JT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= NWTmWo15OjFzN{C5PFg>
KHYG-1 NW\4TIo6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHkToMyKM7:TR?= MmfPNlQhcA>? MlTYVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi MVWyNVE4ODl6OB?=
SNT-16 M4nNTWFxd3C2b4Ppd{BCe3OjeR?= NWC4eJExOSEQvF2= M4rreVYhcA>? Ml\qTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NHrtR|EzOTF5MEm4PC=>
Jurkat M2nxOWFxd3C2b4Ppd{BCe3OjeR?= NEjK[m0yKM7:TR?= MlnVOkBp MlTUTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? M2fVWlIyOTdyOUi4
KAI-3 M4fqSGFxd3C2b4Ppd{BCe3OjeR?= NH;NeIoyKM7:TR?= NUXQeFNLPiCq MVLJcoR2[2W|IHPlcIwh[XCxcITvd4l{ NFTn[WozOTF5MEm4PC=>
KHYG-1 MWnBdI9xfG:|aYOgRZN{[Xl? MU[xJO69VQ>? NYLSRodWPiCq NYrn[Yw{UW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= Mmr5NlEyPzB7OEi=
SNT-13 M1;vd2FvfGm4aYLhcEBCe3OjeR?= NXv2eVlzOSEQvF2= NVTIRoFDOjRiaB?= NYfSWIs4UW6mdXPld{BtgXSrYzDpcoZm[3Srb36gc4YhTUKY MkHWNlEyPzB7OEi=
SNT-16 M{fHfWFvfGm4aYLhcEBCe3OjeR?= MX2xJO69VQ>? MVqyOEBp MWjJcoR2[2W|IHz5eIlkKGmwZnXjeIlwdiCxZjDFRnY> M3nRelIyOTdyOUi4
KAI-3 M4nSfWFvfGm4aYLhcEBCe3OjeR?= Mn\LNUDPxE1? Mo[5NlQhcA>? M3GyPGlv\HWlZYOgcJl1cWNiaX7m[YN1cW:wIH;mJGVDXg>? NVPJdIlLOjFzN{C5PFg>
SNK-6 MkDRRY51cX[rcnHsJGF{e2G7 NUjz[WszOSEQvF2= MXKyOEBp NF\KNodKdmS3Y3XzJIx6fGmlIHnu[oVkfGmxbjDv[kBGSlZ? NXToXW1pOjFzN{C5PFg>
RAW 264.7 MmfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPrXFUyODBibl2= NYjnVFY{PDhiaB?= MULS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? NYT0[INLOjJ2MkexOVQ>
A375 MYLBdI9xfG:|aYOgRZN{[Xl? MWexNEBvVQ>? MYiyOEBp NFi3UnpKdmS3Y3XzJINmdGxiYYDvdJRwe2m| MYCyN|A4QTB6Mx?=
BLM MUjBdI9xfG:|aYOgRZN{[Xl? NXLwS5RwOTBibl2= NETJbG8zPCCq NWT3SY9qUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MWeyN|A4QTB6Mx?=
A375 M{\qcGF2fG:yaHHnfUBCe3OjeR?= NF;vbWMyOCCwTR?= MnXPNVIhcA>? MknUTY5lfWOnczDmc5Ju[XSrb36gc4Yh[XW2b4DoZYdwe2:vZYO= M13wRVI{ODd7MEiz
BLM MkDSRZV1d3CqYXf5JGF{e2G7 MX2xNEBvVQ>? MkLqNVIhcA>? NHzZdnRKdmS3Y3XzJIZwem2jdHnvckBw\iCjdYTvdIhi\2:|b33ldy=> MnPiNlMxPzlyOEO=
H1299 MUPBdI9xfG:|aYOgRZN{[Xl? MkPuPFAhdk1? NYDPTW41OjRiaB?= MX\EUXNQ NYP1T21EW2Wwc3n0bZpmeyCQU1PMR{Bk\WyuczD0c{BOW0NvZHXybZZm\CCrQ{mtbY5lfWOnZDDhdI9xfG:|aYO= NHrhPYEzPTN{M{[5Ny=>
Hut-78 Mk\ESpVv[3Srb36gRZN{[Xl? NID5[nQyODBibl2= MYWyOEBp NWrWfFhWTE2VTx?= NI\vU4RFd3ewcnXneYxifGW|IGTHSk3PujFiYX7kJGlNNTFyIHX4dJJme3Orb36= MYqyOVY5OTN|NR?=
H9 NEfWUVhHfW6ldHnvckBCe3OjeR?= MVyxNFAhdk1? NUO2WmUzOjRiaB?= NFGydphFVVOR NIT0VVhFd3ewcnXneYxifGW|IGTHSk3PujFiYX7kJGlNNTFzIHX4dJJme3Orb36= NFi5e24zPTZ6MUOzOS=>
HH NFXodGpHfW6ldHnvckBCe3OjeR?= NFTxdIsyODBibl2= NIGwdXIzPCCq NXnZdVJ6TE2VTx?= MV;kc5dvemWpdXzheIV{KFSJRj5OtlEh[W6mIFnMMVEzKGW6cILld5Nqd25? NGi1XVIzPTZ6MUOzOS=>
Hut-78 MV7NbYdz[XSrb36gRZN{[Xl? M3LLVVExOCCwTR?= M3P3NFI1KGh? MYnEUXNQ MYTS[YR2[2W|IHPlcIwhdWmpcnH0bY9vKGK7IEiw5qCUQTBn NW\kXFRMOjV4OEGzN|U>
HH NXjEWFVDVWmpcnH0bY9vKEG|c3H5 M3\VSlExOCCwTR?= MoXNNlQhcA>? NUnabJdrTE2VTx?= NVnjPG1nWmWmdXPld{Bk\WyuIH3p[5JifGmxbjDifUA5OOLCk{mxKS=> MWOyOVY5OTN|NR?=
U937 Mm\qSpVv[3Srb36gRZN{[Xl? NGjjeosyODBibl2= NEDTeoM3KGh? M2nHd2lv\HWlZYOgTWwuQCCneIDy[ZN{cW:wIHnuJGxRWy2|dHnteYxifGWmIGW5N|chdWGlcn;wbIFo\XN? NYXMfog{OjV5OUG0O|c>
human PBMC MY\GeY5kfGmxbjDBd5NigQ>? MmP1NVAxKG6P MVmyOEBp NIXD[W9KdmS3Y3XzJGlNNThicnXs[YF{\Q>? Mmr0NlU4QTF2N{e=
ES6 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3DUG5KSzVyPUCuNFAzOSCwTR?= NHzDd5FUSU6JRWK=
SK-UT-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\nTWM2OD1yLkG2N{BvVQ>? Mn3wV2FPT0WU
SH-4 MoT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnFfVBKSzVyPUCuNVc{KG6P MkPzV2FPT0WU
TE-9 MnTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTBwMUiyJI5O MW\TRW5ITVJ?
A253 M{DKNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\ESWlEPTB;MD6yNFghdk1? NXrPSVhvW0GQR1XS
no-10 NXOyVod2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfmTWM2OD1yLkKxJI5O MXjTRW5ITVJ?
MMAC-SF M3L0RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjTfW1KSzVyPUCuNlE3KG6P MVvTRW5ITVJ?
A101D NIHubplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkGxTWM2OD1yLkKyOUBvVQ>? MlHmV2FPT0WU
NTERA-S-cl-D1 NUPLRpZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTBwMkSzJI5O MXjTRW5ITVJ?
8-MG-BA NV7sUopzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjxV3NKSzVyPUCuNlUhdk1? NFn3eHlUSU6JRWK=
KNS-42 NXTwXo1WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLyTWM2OD1yLkK1PEBvVQ>? NGf4fYRUSU6JRWK=
LXF-289 NVvIT4JYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nzPGlEPTB;MD6yOlkhdk1? MUTTRW5ITVJ?
OVCAR-4 M{DDVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzB[41YUUN3ME2wMlI5QSCwTR?= NX7vNY5YW0GQR1XS
LOUCY NVTKNI5FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3L2SmlEPTB;MD6yPVMhdk1? M3jsOHNCVkeHUh?=
BB65-RCC MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLRTWM2OD1yLkOwOEBvVQ>? MoDxV2FPT0WU
D-542MG MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzZZVltUUN3ME2wMlMzQSCwTR?= NFzlSVZUSU6JRWK=
ONS-76 NVnXSFR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3H0[2lEPTB;MD6zN{BvVQ>? Mn3BV2FPT0WU
BB30-HNC M1jmR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFryUFBKSzVyPUCuN|M2KG6P NV3NVpREW0GQR1XS
KS-1 NWm2SmRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTBwM{Sgcm0> M{XSe3NCVkeHUh?=
A388 NY[0ZW55T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jRe2lEPTB;MD6zOVYhdk1? MUPTRW5ITVJ?
ES8 NGT3WmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLJTWM2OD1yLkSgcm0> Ml;iV2FPT0WU
MZ2-MEL MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIq4XnZKSzVyPUCuOFA4KG6P MVXTRW5ITVJ?
HCC2998 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHz1OVJKSzVyPUCuOFEzKG6P NGqwPGdUSU6JRWK=
D-247MG M1zVUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX30XIZCUUN3ME2wMlQyOyCwTR?= NVzye3JIW0GQR1XS
ACN NF30bHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTBwNEG3JI5O NGrxcYJUSU6JRWK=
LB2518-MEL NEHOR49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFH1UZZKSzVyPUCuOFI2KG6P NFGzemRUSU6JRWK=
ES1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn6zTWM2OD1yLkSzJI5O NHS5[lFUSU6JRWK=
HCE-T MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3L1[WlEPTB;MD60N|khdk1? NGDtV2tUSU6JRWK=
OS-RC-2 MlWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\6TWM2OD1yLkS0JI5O NVnmPI97W0GQR1XS
MFH-ino NETnOFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTPTWM2OD1yLkS0N{BvVQ>? MlGzV2FPT0WU
OCUB-M Moq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3vd5JKSzVyPUCuOFQ4KG6P M132THNCVkeHUh?=
CP66-MEL NWP0[oY2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nFc2lEPTB;MD60O|Mhdk1? NF\NSFZUSU6JRWK=
LB771-HNC NHz3PXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnOcWJKSzVyPUCuOFc1KG6P MXzTRW5ITVJ?
DSH1 NXjHSnk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTBwNEigcm0> MW\TRW5ITVJ?
HUTU-80 NY\NVllET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTBwNUOzJI5O M4XMPHNCVkeHUh?=
CESS NHXwVpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXe2bZZVUUN3ME2wMlU{QCCwTR?= NVH1XnpkW0GQR1XS
NCI-H747 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkT5TWM2OD1yLkWzPUBvVQ>? NHrsNZpUSU6JRWK=
HT-144 M2rpWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zUeWlEPTB;MD61O|Yhdk1? NH3YRYxUSU6JRWK=
COLO-829 NIrN[mJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnFfVdKSzVyPUCuOlE1KG6P MWTTRW5ITVJ?
A4-Fuk NVLIZY5XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTBwNkKzJI5O NWq5SVR5W0GQR1XS
GI-ME-N NGK2UmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3Sd4lKSzVyPUCuOlM1KG6P M36zTnNCVkeHUh?=
LB831-BLC NXHjRY5OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrnNm1lUUN3ME2wMlY1OSCwTR?= MVzTRW5ITVJ?
HOP-62 NXTxdnk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFu3fZRKSzVyPUCuOlQ4KG6P M3PVZ3NCVkeHUh?=
BB49-HNC MlToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUT1Z2cxUUN3ME2wMlY2OiCwTR?= M3r3NHNCVkeHUh?=
D-336MG MlLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXv[IFKSzVyPUCuOlU4KG6P MWXTRW5ITVJ?
TK10 M4nDWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TUU2lEPTB;MD62O|khdk1? NUXDfmdJW0GQR1XS
Ramos-2G6-4C10 M3PBOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\YS3lbUUN3ME2wMlY6OyCwTR?= NHrMfHpUSU6JRWK=
LB373-MEL-D M2f4NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2X2TGlEPTB;MD63JI5O M{D2SXNCVkeHUh?=
SF126 M3vse2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnSxTWM2OD1yLkewNUBvVQ>? Mnr4V2FPT0WU
UACC-257 MkTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jUXmlEPTB;MD63NUBvVQ>? MUnTRW5ITVJ?
KINGS-1 NV;STZlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjre3hKSzVyPUCuO|IzKG6P NX7SWIplW0GQR1XS
LS-513 M4mwR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjqbllYUUN3ME2wMlc{QSCwTR?= M2O3T3NCVkeHUh?=
GI-1 M{[3OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrmTWM2OD1yLke2OEBvVQ>? Mm\LV2FPT0WU
ES7 Ml3US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvhTWM2OD1yLke2OkBvVQ>? MXLTRW5ITVJ?
LB2241-RCC M{XvRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTBwOEC0JI5O MmHnV2FPT0WU
D-263MG MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3VTWM2OD1yLkiwO{BvVQ>? MnnJV2FPT0WU
SW684 NFLQTZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4Hi[GlEPTB;MD64NlEhdk1? NFzy[nJUSU6JRWK=
ML-2 NFXMclBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfOTWM2OD1yLkiyNUBvVQ>? M1Tn[3NCVkeHUh?=
SK-LMS-1 Mn3LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3y5VGlEPTB;MD64OVQhdk1? NF2yRYxUSU6JRWK=
TE-5 MkXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TqPWlEPTB;MD64OlUhdk1? NVG4SJo4W0GQR1XS
QIMR-WIL NHT1XWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XNbGlEPTB;MD64PFkhdk1? M4W4U3NCVkeHUh?=
NCI-H1355 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\UUo1KSzVyPUCuPFk2KG6P NHGxUVJUSU6JRWK=
SNB75 Mnf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvPW3hKSzVyPUCuPVEzKG6P MYTTRW5ITVJ?
RXF393 NF3TTVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jETmlEPTB;MD65NVQhdk1? M37E[nNCVkeHUh?=
IST-MEL1 Mn\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTBwOUG3JI5O MmPmV2FPT0WU
SF268 MmDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTBwOUKzJI5O NGXjdmFUSU6JRWK=
KALS-1 M1;6Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\EbYhKSzVyPUCuPVI2KG6P MlXuV2FPT0WU
HC-1 MmnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPBTWM2OD1yLkm3OUBvVQ>? MnL5V2FPT0WU
SW872 NEfRflBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWf2O2dyUUN3ME2wMlk6PiCwTR?= MYLTRW5ITVJ?
PSN1 M1q0Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrBUVRKSzVyPUGuNFEhdk1? MWXTRW5ITVJ?
TE-1 NUnFUnh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7keohXUUN3ME2xMlA{KG6P M4[zenNCVkeHUh?=
TE-10 NFTJdI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnJcWxIUUN3ME2xMlA{KG6P NHK2b4dUSU6JRWK=
RKO MljqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrpPWhSUUN3ME2xMlA3KG6P NF\H[GVUSU6JRWK=
LC-2-ad MkTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTFwMEigcm0> MV\TRW5ITVJ?
SK-MM-2 NVXyd3JQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MliyTWM2OD1zLkC5JI5O NVXTdoxbW0GQR1XS
VA-ES-BJ MmCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTFwMEmgcm0> M{nkb3NCVkeHUh?=
MZ7-mel MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{P1N2lEPTB;MT6wPUBvVQ>? NUX5RoZ{W0GQR1XS
D-392MG NX3FTIVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jufGlEPTB;MT6xJI5O MkS5V2FPT0WU
CCRF-CEM NUfDfYxRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3Xp[GlEPTB;MT6xN{BvVQ>? MXjTRW5ITVJ?
EM-2 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPFb25KSzVyPUGuNVYhdk1? NFvzZYhUSU6JRWK=
HAL-01 MkTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LHOmlEPTB;MT6xPEBvVQ>? MlnnV2FPT0WU
TE-8 M17rbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoW3TWM2OD1zLkG5JI5O NYW5NYlUW0GQR1XS
NCI-H1882 NEnN[YdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHsOXdXUUN3ME2xMlIhdk1? MnGxV2FPT0WU
Daudi MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXpTWM2OD1zLkKyJI5O NHjGfo1USU6JRWK=
BL-41 MnrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nWeWlEPTB;MT6yOUBvVQ>? NUTaOFFWW0GQR1XS
SR NICwfJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DSWGlEPTB;MT6yOUBvVQ>? NGK5WGFUSU6JRWK=
KM12 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XWO2lEPTB;MT6yO{BvVQ>? NYLUOFdGW0GQR1XS
K5 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDYTmtYUUN3ME2xMlI5KG6P MkfGV2FPT0WU
A3-KAW NH;ifFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHDcXVUUUN3ME2xMlI5KG6P NEfoZ5VUSU6JRWK=
CMK M2fweWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX[3bmloUUN3ME2xMlI6KG6P MmLCV2FPT0WU
Calu-6 MoTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTFwMkmgcm0> Mne4V2FPT0WU
IST-SL2 NWjBTXJqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrEbnRiUUN3ME2xMlMyKG6P NE\vVm5USU6JRWK=
OPM-2 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TRXGlEPTB;MT6zN{BvVQ>? MWjTRW5ITVJ?
DU-4475 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTsZm1oUUN3ME2xMlM3KG6P NWrOc5kyW0GQR1XS
ECC12 MnPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTFwM{egcm0> Mn36V2FPT0WU
L-540 NGX6W5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfsfHNKSzVyPUGuN|chdk1? NVXlbo1GW0GQR1XS
CAS-1 NEDx[3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUS4bYFZUUN3ME2xMlM4KG6P NF;2ZnRUSU6JRWK=
PF-382 NYewXHpTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;TfGlEPTB;MT60O{BvVQ>? NIX5NppUSU6JRWK=
LS-411N MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTFwNUOgcm0> MlnRV2FPT0WU
NCI-H69 M2nqTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3NSIZKSzVyPUGuOVQhdk1? MnnvV2FPT0WU
NB12 NHXudmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfjTWM2OD1zLkW2JI5O NFnCR4NUSU6JRWK=
HEL MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3X2fGlEPTB;MT62NUBvVQ>? NXXzbHkzW0GQR1XS
GCIY M1TPPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;WT2lEPTB;MT62NkBvVQ>? MXnTRW5ITVJ?
EHEB NUXoPXlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XPWWlEPTB;MT62O{BvVQ>? NH;NXWZUSU6JRWK=
TGBC1TKB NIflVYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrs[IwyUUN3ME2xMlcyKG6P M321fXNCVkeHUh?=
KURAMOCHI NXPNdHNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\RepBKSzVyPUGuO|Ihdk1? NEG2ZlhUSU6JRWK=
U-266 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTnfGV[UUN3ME2xMlc3KG6P MUDTRW5ITVJ?
LC4-1 NXvOTpM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDyRoRKSzVyPUGuO|khdk1? NH7wRppUSU6JRWK=
NCI-H2126 NE\iV2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTsTWM2OD1zLkigcm0> MWfTRW5ITVJ?
NCI-H1092 MkOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;yeWVyUUN3ME2xMlghdk1? MU\TRW5ITVJ?
GB-1 NU\Kc3BFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTFwOEGgcm0> NIf4Z4ZUSU6JRWK=
MV-4-11 NUnoRm9XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTFwOEKgcm0> M4j6ZnNCVkeHUh?=
Becker MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn:4TWM2OD1zLkizJI5O NYDOdJU4W0GQR1XS
MPP-89 NEHvb21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWf1SoVJUUN3ME2xMlg6KG6P NVnCUphzW0GQR1XS
BE-13 NY\HdpBpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDFS5VKSzVyPUGuPVMhdk1? NWDGPYpZW0GQR1XS
697 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTiPINUUUN3ME2xMlk6KG6P NFjjXVZUSU6JRWK=
NKM-1 Mnm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmf2TWM2OD1{IH7N MWPTRW5ITVJ?
NB13 MmfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rGSmlEPTB;MjDuUS=> MmjlV2FPT0WU
LS-123 NH7GW|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXkO4hPUUN3ME2yMlAzKG6P MW\TRW5ITVJ?
NB17 M3vqfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkftTWM2OD1{LkC0JI5O NEXjOJlUSU6JRWK=
LAN-6 NXnG[5E2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;PS2lEPTB;Mj6wOUBvVQ>? MVHTRW5ITVJ?
EW-24 M3r4b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV74No5pUUN3ME2yMlA5KG6P M{\CfXNCVkeHUh?=
NOS-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nsPGlEPTB;Mj6xNUBvVQ>? M2\JenNCVkeHUh?=
BL-70 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTJwMUKgcm0> M{[2dnNCVkeHUh?=
GT3TKB MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFT0c4FKSzVyPUKuNVIhdk1? MV;TRW5ITVJ?
HH NGnyVWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXycVZKSzVyPUKuNVMhdk1? NULkdYx4W0GQR1XS
KE-37 NWDqdJR{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUH4PG12UUN3ME2yMlE{KG6P NEjkc2dUSU6JRWK=
MOLT-4 NUHidXJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\pTWM2OD1{LkGzJI5O Mnf0V2FPT0WU
EKVX NUHET2drT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vmfmlEPTB;Mj6xOEBvVQ>? M2\3TnNCVkeHUh?=
KGN M4nVeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnyU|U5UUN3ME2yMlE2KG6P NHjrd2xUSU6JRWK=
ES4 NHzz[WxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LZNWlEPTB;Mj6xOkBvVQ>? M1\aW3NCVkeHUh?=
SJSA-1 NXfsXphHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTJwMkGgcm0> NX3MWXY3W0GQR1XS
KMOE-2 M3ixcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHjTWM2OD1{LkKzJI5O MUfTRW5ITVJ?
NB5 NHrsd2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLZeXJCUUN3ME2yMlI4KG6P M3fO[nNCVkeHUh?=
BC-1 MlfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTJwM{Ggcm0> Mnv2V2FPT0WU
NB10 NH63RZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTJwM{Kgcm0> Mon2V2FPT0WU
RPMI-8226 MmHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33wcWlEPTB;Mj6zOUBvVQ>? M4XhZnNCVkeHUh?=
SCC-3 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHz5NIlKSzVyPUKuN|chdk1? M4CwWXNCVkeHUh?=
ARH-77 NGK4NolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zxNmlEPTB;Mj6zPEBvVQ>? NGTkU2ZUSU6JRWK=
NCI-H748 NXL4fGYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDVTWM2OD1{LkO5JI5O NFTEVZZUSU6JRWK=
KU812 NF[xcYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUL3SIZDUUN3ME2yMlQzKG6P M1vKSnNCVkeHUh?=
NCI-H64 NHnUV3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTJwNESgcm0> NY\J[XZ6W0GQR1XS
NB69 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nsTmlEPTB;Mj60OkBvVQ>? M1;0bnNCVkeHUh?=
KNS-81-FD NYrvT|EzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;qR2RZUUN3ME2yMlQ5KG6P M1vuNXNCVkeHUh?=
LB1047-RCC NVjqeJBrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fSVGlEPTB;Mj61O{BvVQ>? NVf0dlREW0GQR1XS
EB-3 NGHPR29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTJwNk[gcm0> M17udXNCVkeHUh?=
Mo-T NXjMT4t2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjofGxKSzVyPUKuO|Qhdk1? MlXXV2FPT0WU
EW-16 M{jSfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPiV4o1UUN3ME2yMlc2KG6P MlzkV2FPT0WU
CTV-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPnUoxKSzVyPUKuPEBvVQ>? NHXQ[HBUSU6JRWK=
ETK-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnPZm9kUUN3ME2yMlg1KG6P NXWw[5o5W0GQR1XS
C2BBe1 NYHaVG16T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;tPXhbUUN3ME2yMlg6KG6P M1f0NXNCVkeHUh?=
MOLT-16 NFTZT41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rM[GlEPTB;Mj64PUBvVQ>? MljVV2FPT0WU
SW954 NGjOVohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvHbo9KSzVyPUKuPUBvVQ>? MWTTRW5ITVJ?
HT NIPvb2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLCTWM2OD1|LkCyJI5O MVLTRW5ITVJ?
KARPAS-299 Mn\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7UeG9kUUN3ME2zMlA3KG6P MlvBV2FPT0WU
MONO-MAC-6 NEDQVXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLuVlJKSzVyPUOuNUBvVQ>? NWLyZpc2W0GQR1XS
CGTH-W-1 NH3Od5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTNwMTDuUS=> NX7Bb4VtW0GQR1XS
SK-PN-DW MmjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HNeWlEPTB;Mz6xOEBvVQ>? M1;IVnNCVkeHUh?=
CW-2 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfyTWM2OD1|LkKxJI5O MVjTRW5ITVJ?
SK-N-DZ NH;q[|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIO3WnZKSzVyPUOuNlYhdk1? NGnhVmhUSU6JRWK=
NEC8 NVHnOlFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrzO|VJUUN3ME2zMlM2KG6P NFzQRoJUSU6JRWK=
LB996-RCC NXXjXGZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEX1eYJKSzVyPUOuOEBvVQ>? NX7XUYlOW0GQR1XS
DB M1zRdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFToNVVKSzVyPUOuOFEhdk1? NFHzdndUSU6JRWK=
TE-15 MonpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjMbZhwUUN3ME2zMlQ{KG6P NGfESnZUSU6JRWK=
COR-L88 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTNwNEegcm0> NWrWd5ZGW0GQR1XS
LAMA-84 NEf0WIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTNwNEmgcm0> NVfYOXpGW0GQR1XS
MEG-01 MkTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLSdFNKSzVyPUOuOFkhdk1? NX\XPVdQW0GQR1XS
LOXIMVI Ml;3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE[wPJFKSzVyPUOuOUBvVQ>? M1W4UnNCVkeHUh?=
RPMI-8402 M1\FVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXhNphlUUN3ME2zMlUhdk1? NE\2dlBUSU6JRWK=
KARPAS-45 NWn2fpJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3z6VWlEPTB;Mz61OEBvVQ>? MmrKV2FPT0WU
HCC1187 M4rOU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonXTWM2OD1|LkW0JI5O MYjTRW5ITVJ?
MZ1-PC NIP6SZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTNwNUSgcm0> M4PFXnNCVkeHUh?=
no-11 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7BbIp7UUN3ME2zMlU2KG6P M2K2e3NCVkeHUh?=
EVSA-T M2LtN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTNwNjDuUS=> NILDUHpUSU6JRWK=
DJM-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HiSGlEPTB;Mz62N{BvVQ>? NHTuW5ZUSU6JRWK=
COLO-684 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\UfGlEPTB;Mz62OkBvVQ>? NHzTfohUSU6JRWK=
NMC-G1 NGHtXWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvTS5lKSzVyPUOuOlghdk1? NXPCRpZMW0GQR1XS
LC-1F NWHOcZhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTNwN{Sgcm0> NXTwdlJ6W0GQR1XS
RL95-2 M{iyPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\LOJpKSzVyPUOuO|khdk1? M4fBNHNCVkeHUh?=
COLO-320-HSR NW\oZVR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPic2tJUUN3ME2zMlkzKG6P NXrFUmFbW0GQR1XS
RCC10RGB NW\sNmNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPOTWM2OD1|LkmzJI5O MUHTRW5ITVJ?
HD-MY-Z NV;icWo{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nWZmlEPTB;Mz65N{BvVQ>? MonqV2FPT0WU
NCI-H2141 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFS1dWZKSzVyPUSuNFUhdk1? NVr2S2JoW0GQR1XS
K-562 NELEbINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3udYNKSzVyPUSuNVIhdk1? M4S0enNCVkeHUh?=
NCI-H1648 M4fTd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\Qc2lEPTB;ND6xN{BvVQ>? MYjTRW5ITVJ?
OMC-1 M1[2fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTsVmlnUUN3ME20MlE5KG6P MmPOV2FPT0WU
LB647-SCLC NITyZ2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV[yVWVGUUN3ME20MlIzKG6P NH[1UnpUSU6JRWK=
TE-12 NFTZfGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnWTWM2OD12LkK1JI5O M1TtVXNCVkeHUh?=
NOMO-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTRwM{Ogcm0> NIjUPINUSU6JRWK=
Raji NFLXfXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTRwNE[gcm0> MnvXV2FPT0WU
NALM-6 NWric|ZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jG[2lEPTB;ND60PUBvVQ>? NG\4VIpUSU6JRWK=
HL-60 M37aW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PXVGlEPTB;ND62O{BvVQ>? MnriV2FPT0WU
IST-SL1 MmXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTRwNkigcm0> Mm\jV2FPT0WU
MHH-PREB-1 NWT5fnN5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTRwOE[gcm0> M2nQeHNCVkeHUh?=
MHH-NB-11 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTRwOUGgcm0> M1TS[nNCVkeHUh?=
JiyoyeP-2003 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGL5bIZKSzVyPUWgcm0> MVXTRW5ITVJ?
SBC-1 NHnvS|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rPSGlEPTB;NT6wNUBvVQ>? MXXTRW5ITVJ?
CHP-126 Mkf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PneWlEPTB;NT6wOkBvVQ>? NWnUfYVTW0GQR1XS
LU-139 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPy[VNKSzVyPUWuNVMhdk1? MlHSV2FPT0WU
NCI-SNU-5 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTVwMUegcm0> MVfTRW5ITVJ?
SW962 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHKToJKSzVyPUWuNlEhdk1? M2X6fXNCVkeHUh?=
EW-1 NGrqfWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4q5[GlEPTB;NT6zNUBvVQ>? MmDBV2FPT0WU
NCI-H1417 NXrKUG5VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUSxPIpwUUN3ME21MlUyKG6P M1u5OnNCVkeHUh?=
LU-65 NYjNV3JuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;5VmlEPTB;NT64OEBvVQ>? NVn5V|V3W0GQR1XS
D-502MG NHL6R2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoOxTWM2OD14LkO3JI5O NET2em5USU6JRWK=
BC-3 M4Xqbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDTUY9EUUN3ME22MlYyKG6P NH:yNplUSU6JRWK=
GDM-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjFfppmUUN3ME22Mlc4KG6P NXGycIl5W0GQR1XS
NCI-H2196 Mm\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPHTWM2OD14Lkigcm0> NWTrcnkzW0GQR1XS
NB1 MojYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzLTWM2OD14Lki4JI5O MV\TRW5ITVJ?
NCI-H345 MnrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zZdmlEPTB;Nz6yJI5O M1jBSXNCVkeHUh?=
SU-DHL-1 NYP2NXhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTdwMkSgcm0> NFrvN4JUSU6JRWK=
JVM-2 M{L0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGW0Z5VKSzVyPUeuNlghdk1? NIfVdG5USU6JRWK=
LU-134-A MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE[5d3dKSzVyPUeuN|khdk1? NHziT|VUSU6JRWK=
NCI-H1694 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWT3VVQyUUN3ME23MlU5KG6P MVPTRW5ITVJ?
NCI-SNU-16 NHrCW2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorNTWM2OD15Lk[1JI5O NF7VTYpUSU6JRWK=
L-363 NFjjPWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLaTWM2OD15Lkegcm0> MnfHV2FPT0WU
KG-1 NWTDRmR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnZVo1KSzVyPUeuPVQhdk1? MkfWV2FPT0WU
MN-60 NILQfWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrydnppUUN3ME24MlE1KG6P MYfTRW5ITVJ?
NB6 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mom5TWM2OD16LkS4JI5O NXXHSXJjW0GQR1XS
MLMA MoizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrOZWxtUUN3ME24Mlg2KG6P NIC1cm9USU6JRWK=
ATN-1 NH3XXVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXFTWM2OD16Lki5JI5O MnTuV2FPT0WU
SK-NEP-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTlwMEGgcm0> M1XrNHNCVkeHUh?=
DMS-114 NGj1TVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnu2TWM2OD17Lk[yJI5O NV\Yd5FLW0GQR1XS
CTB-1 NHTabnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrFTWM2OD17Lk[3JI5O MUHTRW5ITVJ?
NCI-H2081 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTFyLkC5JI5O NGHjeYZUSU6JRWK=
ES5 NF;EPWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfQTWM2OD1zMD6zPEBvVQ>? MULTRW5ITVJ?
HCC1599 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHLeYh[UUN3ME2xNU46OSCwTR?= MofPV2FPT0WU
NCI-H23 NEH2[mdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\icmlEPTB;MUKuNVIhdk1? NVHZXWZZW0GQR1XS
NCI-H1581 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mni0TWM2OD1zMj6yPEBvVQ>? NHTFc4hUSU6JRWK=
JVM-3 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX:z[VZJUUN3ME2xNk46QSCwTR?= MVrTRW5ITVJ?
NCI-SNU-1 Mmj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH64TlhKSzVyPUGzMlE6KG6P M17BWHNCVkeHUh?=
NB7 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnz1TWM2OD1zNT65NkBvVQ>? Mlf4V2FPT0WU
JAR NFrCSGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTF4LkGzJI5O Mle2V2FPT0WU
TGW NVq4OI9JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPxNJh6UUN3ME2xOk41QCCwTR?= MoOyV2FPT0WU
U-87-MG NXq2WZJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTF4Lke2JI5O MWXTRW5ITVJ?
NCI-H1436 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DI[mlEPTB;MUeuNFEhdk1? NUfoVZZ4W0GQR1XS
GOTO Mk\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3hOYtvUUN3ME2xO{4xPiCwTR?= NXO0U3N{W0GQR1XS
COLO-800 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfBTWM2OD1zNz62OEBvVQ>? NVHwcY5lW0GQR1XS
MFM-223 M1fWbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnOO2lNUUN3ME2xO{46OSCwTR?= NF72OY5USU6JRWK=
EW-18 NUO1XVhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;yfYo5UUN3ME2xO{46PiCwTR?= NEnz[YRUSU6JRWK=
NB14 NYXaTplDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTF5Lkm4JI5O NYL3dpUxW0GQR1XS
EB2 NE\odJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTF6LkC4JI5O NWnESFVZW0GQR1XS
EoL-1- M13rOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTF6LkOxJI5O M3;4dnNCVkeHUh?=
NCCIT MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXpTWM2OD1zOD6zOkBvVQ>? NYK3Oo1nW0GQR1XS
DG-75 Ml7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFL6OnNKSzVyPUG4MlYyKG6P NYGyWFdWW0GQR1XS
HCC2218 MkO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTF7LkWgcm0> NHvkVY9USU6JRWK=
TE-6 NYLLUoJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvDWVBHUUN3ME2yNE4xQCCwTR?= MWfTRW5ITVJ?
SF539 NYjYSWNRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HDRmlEPTB;MkCuOlchdk1? MVnTRW5ITVJ?
NCI-H446 M3:xTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmX0TWM2OD1{MT6xPEBvVQ>? M1v2bnNCVkeHUh?=
IST-MES1 MmLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDuUoZkUUN3ME2yNk44PyCwTR?= NV3TNopjW0GQR1XS
NCI-H82 M{WyfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4P4eWlEPTB;MkOuNFIhdk1? Ml7aV2FPT0WU
HCC2157 NIXU[odIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3O1U2lEPTB;MkOuNVMhdk1? M37kWnNCVkeHUh?=
EW-12 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYm0d|dRUUN3ME2yN{4yPyCwTR?= M2rPV3NCVkeHUh?=
SIMA M3LBVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTJ|LkO4JI5O MoXIV2FPT0WU
DOHH-2 MlL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\iUnhUUUN3ME2yN{41PSCwTR?= NUe5bVNlW0GQR1XS
IM-9 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEf1XVVKSzVyPUKzMlU1KG6P MnjaV2FPT0WU
EC-GI-10 NHfYWXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{D3ZWlEPTB;MkSuNlMhdk1? MUPTRW5ITVJ?
HDLM-2 M{nSZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTJ2LkW0JI5O MknwV2FPT0WU
LS-1034 MlHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPvW4Y{UUN3ME2yOU44PSCwTR?= MUDTRW5ITVJ?
REH MmDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{j3bGlEPTB;Mk[uOFEhdk1? M2j0enNCVkeHUh?=
LU-165 NHHuTW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTJ4LkeyJI5O MnnHV2FPT0WU
NH-12 MnTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DtOWlEPTB;MkeuOlchdk1? MVvTRW5ITVJ?
WSU-NHL Mn7JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3tTWM2OD1{OD6zPUBvVQ>? MlrZV2FPT0WU
ECC4 MmXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fqO2lEPTB;MkiuO|khdk1? M{P5[HNCVkeHUh?=
OCI-AML2 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\2TWM2OD1{OT62PUBvVQ>? NGDXTXlUSU6JRWK=
EW-3 NHW5fVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTNyLkW5JI5O MUPTRW5ITVJ?
NCI-H526 MmjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvSNmszUUN3ME2zNk42PCCwTR?= NX;JTllIW0GQR1XS
NCI-H719 NVXkNlZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHTSXFKSzVyPUO0MlMyKG6P M1:2bXNCVkeHUh?=
KARPAS-422 MlHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\JTWM2OD1|NT6wOEBvVQ>? MWnTRW5ITVJ?
SK-MEL-1 NGXZ[GpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4Ple2lEPTB;M{WuNVchdk1? M2nBXnNCVkeHUh?=
ES3 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTN3LkG5JI5O NFvnN5JUSU6JRWK=
UACC-812 NH;TOXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TrPGlEPTB;M{WuOFQhdk1? NYT3XVBbW0GQR1XS
C8166 NGnhVmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1z3UWlEPTB;M{WuO{BvVQ>? M2\KPHNCVkeHUh?=
MDA-MB-134-VI NFuzN3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTN3Lki3JI5O M4rPVHNCVkeHUh?=
D-283MED NEDlXVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XuVWlEPTB;M{euO|khdk1? M4TwenNCVkeHUh?=
SHP-77 NYHT[GZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUm4[mhyUUN3ME2zPE4xOyCwTR?= M2rsZnNCVkeHUh?=
NCI-H2227 NHzz[YdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLFNXBKSzVyPUSwMlQ6KG6P NV:wPVd1W0GQR1XS
SKM-1 NH:4R|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTR{Lk[zJI5O NEf5O|ZUSU6JRWK=
L-428 NV;nS5JLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nrfWlEPTB;NEOuPFYhdk1? MXXTRW5ITVJ?
RPMI-6666 NV\Yepc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LDdWlEPTB;NEWuPFkhdk1? M{PnOHNCVkeHUh?=
NCI-H716 M3rlNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmW5TWM2OD12OD64NUBvVQ>? NWnOd4M5W0GQR1XS
DMS-79 NVH1VIxPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXiTWM2OD13MD63NUBvVQ>? NHrLOZlUSU6JRWK=
RS4-11 MkPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjwdVNuUUN3ME21NE45QCCwTR?= M2DVXHNCVkeHUh?=
NCI-H720 M3TPb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHIS|dKSzVyPUWxMlEyKG6P NHjJVZhUSU6JRWK=
MC-CAR NGS1bXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYO5VHVlUUN3ME21NU42OiCwTR?= NYLDNnROW0GQR1XS
TALL-1 MmnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PxcGlEPTB;NUOuPVEhdk1? NV\OdYZmW0GQR1XS
NCI-N87 Mli2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\kOVQ4UUN3ME21OE4yQCCwTR?= MmPTV2FPT0WU
P30-OHK MmjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWq5UlNNUUN3ME21OE43OSCwTR?= MoDMV2FPT0WU
LP-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTZzLkK4JI5O M2fpcnNCVkeHUh?=
YT NX71OHdZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTZzLkigcm0> MUXTRW5ITVJ?
MRK-nu-1 NXvhfHo6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTZzLkiyJI5O MlTkV2FPT0WU
BT-474 NW\hOllwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1P2PWlEPTB;NkWgcm0> MkXmV2FPT0WU
NCI-H322M M4PQZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFP2cWZKSzVyPU[2MlEyKG6P NIXEO2JUSU6JRWK=
NCI-H128 MkG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTd2Lke3JI5O NFLqO|dUSU6JRWK=
KMS-12-PE MnS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPETWM2OD15Nj6yOEBvVQ>? NIrsWpZUSU6JRWK=
KP-N-YS NWraeXNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrOVWZpUUN3ME23Ok44PCCwTR?= NIDIV2pUSU6JRWK=
ALL-PO MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYe5OpgyUUN3ME23O{43PiCwTR?= MV7TRW5ITVJ?
EW-13 NF65OINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojxTWM2OD15Nz63OkBvVQ>? MYfTRW5ITVJ?
EW-11 NI\jbnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PGXWlEPTB;N{iuOVIhdk1? NEXq[3dUSU6JRWK=
SK-N-FI MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vjdGlEPTB;OECuNkBvVQ>? MYTTRW5ITVJ?
CAL-148 MkKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXvdHBKSzVyPUixMlg1KG6P MlyzV2FPT0WU
RL NHjIPXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2C2UGlEPTB;OE[uNFkhdk1? M2jWU3NCVkeHUh?=
AM-38 M2X2Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jiW2lEPTB;OEiuNFghdk1? NXPZb2pwW0GQR1XS
RH-1 NH\ITIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTl7Lki1JI5O M2PyfnNCVkeHUh?=
NCI-H1770 Ml\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3Sxe2lEPTB;MUCyMlQ6KG6P NUPTe5htW0GQR1XS
SIG-M5 NIj0OHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXtTWM2OD1zMEWuNFYhdk1? M2\nOHNCVkeHUh?=
GR-ST M4DYUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTFzMz6zOEBvVQ>? M4XkTXNCVkeHUh?=
ST486 NIDYPY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\0b2dKSzVyPUGxOE4xPiCwTR?= M{fu[XNCVkeHUh?=
NCI-H1650 M2PoN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfiVndKSzVyPUGxOU4zQSCwTR?= Mo\CV2FPT0WU
MHH-CALL-2 NWDwcphlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzTdoVjUUN3ME2xNVUvPyCwTR?= MWPTRW5ITVJ?
BV-173 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{H5XmlEPTB;MUKyMlcyKG6P NXnvbZV3W0GQR1XS
MC116 M{\KZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTF2OD64OUBvVQ>? MULTRW5ITVJ?
NCI-H524 NU\EN2xnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXSblhKSzVyPUG1PU4yKG6P M{HNWnNCVkeHUh?=
SCLC-21H MlfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\ZdoNxUUN3ME2xOVkvPDFibl2= MUTTRW5ITVJ?
NCI-H1304 NFi2[nhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHXSXIxUUN3ME2xOlkvOjFibl2= MUnTRW5ITVJ?
NCI-H510A NXPIXJdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\tV2dKUUN3ME2xPFUvOzdibl2= M3HtdXNCVkeHUh?=
NCI-H209 M2O1cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjUTWM2OD1zOU[uOVIhdk1? M1W2TnNCVkeHUh?=
KM-H2 NGC4W5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHOTWM2OD1zOUeuNFUhdk1? MnvIV2FPT0WU
NCI-H1395 M2TQfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPkTWM2OD1{MUCuNVMhdk1? NYfhXmYyW0GQR1XS
NCI-H1155 MlvIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3TTWM2OD1{M{CuN|Ihdk1? MWTTRW5ITVJ?
COR-L279 Mkn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTJ3Mj6xO{BvVQ>? MWDTRW5ITVJ?
NCI-H1299 MoPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnV[HNKSzVyPUK2NU44OSCwTR?= NEPPOnJUSU6JRWK=
EW-22 M2O5Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvFXpJKSzVyPUK2N{44PSCwTR?= NWq2VIgzW0GQR1XS
SK-MEL-2 NIHSZ2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTNdmFYUUN3ME2yPFEvQSCwTR?= NF;oWJpUSU6JRWK=
KASUMI-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3S5V2lEPTB;MkizMlA2KG6P M3vpcnNCVkeHUh?=
NCI-H187 NEeyeJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTyTWM2OD1{OEeuNFghdk1? MXXTRW5ITVJ?
NCI-H2171 M13GXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnVVZRKSzVyPUK4PE46OiCwTR?= NWDaW5FEW0GQR1XS
LNCaP-Clone-FGC M4\tXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTJ7NT6yOkBvVQ>? NUnqOW85W0GQR1XS
NCI-H1522 NU\ZdXdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTNyNz6wOUBvVQ>? NYf2T|RPW0GQR1XS
SCH MorzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2SxRWlEPTB;M{KyMlIzKG6P Mn;nV2FPT0WU
THP-1 NGXxfW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWK2ZZRiUUN3ME2zNlIvPiCwTR?= MVzTRW5ITVJ?
SNU-C1 MlXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTN4Mj6wPUBvVQ>? M3LEenNCVkeHUh?=
CA46 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnlNJk4UUN3ME2zO|MvPjNibl2= MkLvV2FPT0WU
NCI-H1963 M{SxZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLmTWM2OD1|OE[uNVkhdk1? M2TTR3NCVkeHUh?=
DEL MkPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTN7MT6yO{BvVQ>? NWO2dHFNW0GQR1XS
TUR MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3JTWM2OD1|OU[uOlEhdk1? NUXvSI14W0GQR1XS
NCI-H226 NWC4VWFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPxWHdKSzVyPUSwN{4zOyCwTR?= MmP1V2FPT0WU
COLO-668 NUe2foVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTRyMz61O{BvVQ>? MknOV2FPT0WU
CPC-N MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TFeWlEPTB;NECzMlc4KG6P MoHWV2FPT0WU
NCI-H889 MnztS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXDTWM2OD12NkGuPVIhdk1? MVHTRW5ITVJ?
J-RT3-T3-5 NHzvTY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXER2JKSzVyPUWzNk42PyCwTR?= NIjBR4NUSU6JRWK=
MSTO-211H MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vNVWlEPTB;NUe0MlI3KG6P NFz6Z5RUSU6JRWK=
SCC-15 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PW[mlEPTB;Nk[3MlQ4KG6P NI\jcYVUSU6JRWK=
SUP-T1 M3vUdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFO1WXpKSzVyPU[4Ok4xPCCwTR?= MmXmV2FPT0WU
DMS-153 M1LPc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTd2Nj64N{BvVQ>? NW\T[oU1W0GQR1XS
MS-1 MlLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\YeVZKSzVyPUe1PU41OiCwTR?= NHfBPI9USU6JRWK=
TC-YIK MnrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkewTWM2OD15OEGuNFEhdk1? MYnTRW5ITVJ?
RPMI-8866 NXfLNGdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rzemlEPTB;MUCwOk4zQCEQvF2= M13K[HNCVkeHUh?=
KY821 NH;2[4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\QTWM2OD1zMEO2MlA1KM7:TR?= Ml3hV2FPT0WU
P31-FUJ MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjGO5FKSzVyPUGxNVIvPzVizszN MYXTRW5ITVJ?
COLO-824 MorxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnrR4xKSzVyPUGyOlEvPzhizszN NGK4ZopUSU6JRWK=
U-698-M MkS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3Xs[2lEPTB;MkK2Nk4yPSEQvF2= MYXTRW5ITVJ?
TE-441-T MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHr1Uo9KSzVyPUK1NlEvPyEQvF2= NIj0coFUSU6JRWK=
IMR-5 NUPmfm1tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\vfWlEPTB;M{SwPU43OiEQvF2= NVfMcHA6W0GQR1XS
NCI-H1838 NGfzTVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LKUGlEPTB;NEG4Ok4{OiEQvF2= NXjiXIpYW0GQR1XS

... Click to View More Cell Line Experimental Data

体内研究 Bortezomib单一用药的抗癌作用已在多发性骨髓瘤的异种移植模型,成人白血病,肺癌,乳腺癌,前列腺癌,胰腺癌,头颈癌,和结肠癌,以及在黑色素瘤中得到证实。[2]在Lewis肺癌模型中,口服bortezomib (1.0 mg/ kg,每天),服用18天引起肿瘤生长延迟,并减少转移数量。Bortezomib单一用药, 高达5 mg/kg剂量时显著降低乳腺癌细胞的存活率。在前列腺癌小鼠异种移植模型中,Bortezomib (1.0 mg/kg,每周一次)用药4周减少60%肿瘤生长。1.0 mg/kg Bortezomib给药4周导致胰腺癌小鼠异种移植物生长减少72%或84%,并导致肿瘤细胞凋亡增加。1.0 mg/kg Bortezomib显著抑制人浆细胞瘤异种移植物生长,增加肿瘤细胞凋亡和总存活率,并减少肿瘤血管生成。[3]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[4]

+ 展开

动力学法:

在典型的动力学试验中,2.00 mL试验缓冲液(20 mM HEPES,0.5 mM EDTA,0.035% SDS,pH 7.8) 和 Suc-Leu-Leu-Val-Tyr-AMC溶于DMSO,加入3 mL荧光比色皿中,并将比色皿放置于荧光分光光度计的夹套细胞皿座。反应温度通过循环水浴维持在37℃。反应溶液达到热平衡后(5 分钟),1 μL−10 μL储存酶溶液加入培养皿。伴随AMC 从多肽AMC底物裂解的反应进程通过440 nm (λex= 380 nm)下荧光发射的增加监测。
细胞实验:

[5]

+ 展开
  • Cell lines: 人多发性骨髓瘤细胞系U266
  • Concentrations: ~10 μM
  • Incubation Time: 2天
  • Method:

    通过测定细胞吸收 MTT染料的情况而测定 Bortezomib对 MM和 BMSC 生长的抑制情况。每孔使用10 μL 5 mg/mL MTT对培养48小时的细胞进行脉冲处理,至少处理4小时, 随后加入100 μL 含0.04 N HCl的异丙醇 。使用分光光度计在 570 nm处测定吸光值。


    (Only for Reference)
动物实验:

[3]

+ 展开
  • Animal Models: 人浆细胞瘤异种移植物RPMI 8226
  • Formulation: 生理盐水
  • Dosages: 1mg/kg
  • Administration: i.v.,一周两次,使用4周,然后一周一次
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 76 mg/mL (197.79 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用:
2% DMSO+30% PEG 300+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 384.24
化学式

C19H25BN4O4

CAS号 179324-69-7
稳定性 powder
in solvent
别名 LDP-341, MLM341

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01891968 Completed Leukemia M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. August 7, 2013 Phase 2
NCT01445405 Completed Carcinoma, Squamous|Head and Neck Cancer|Oral Cancer|Laryngeal Cancer|Pharyngeal Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 5, 2008 Phase 1
NCT02211755 Recruiting Neoplasms|Myelodysplastic Syndromes National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 30, 2014 Phase 1
NCT02654990 Recruiting Multiple Myeloma Novartis Pharmaceuticals|Novartis April 27, 2016 Phase 2
NCT00011778 Completed Squamous Cell Carcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 22, 2001 Phase 1
NCT02658396 Withdrawn Multiple Myeloma|Multiple Myeloma in Relapse|Refractory Multiple Myeloma Dana-Farber Cancer Institute|Genus Oncology, LLC|National Institutes of Health (NIH) June 2017 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    On your website, it is mentioned that Bortezomib should be prepared at a concentration of 5 mg/ml in 2% DMSO/30% PEG300/ddH2O for in vivo use. But on the product sheet we received with the compound, it is mentioned: 5mg/ml in 0.5% methylcellulose, 0.2% tween 80. So which is the correct preparation buffer?

  • 回答:

    S1013 Bortezomib in 2% DMSO+30% PEG 300+ddH2O at 5 mg/ml is a clear solution, and it in 0.5% methylcellulose+0.2% Tween 80 is a suspension. Please choose the suitable vehicle according to your administration route. When you prepare the clear solution, please dissolve Bortezomib in DMSO first, make sure it dissolves well, warm it up to 45 degree and/or sonicate if necessary, then add PEG, mix well, and finally add water.

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

相关Proteasome产品

Tags: 购买Bortezomib (PS-341) | Bortezomib (PS-341)供应商 | 采购Bortezomib (PS-341) | Bortezomib (PS-341)价格 | Bortezomib (PS-341)生产 | 订购Bortezomib (PS-341) | Bortezomib (PS-341)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID